Xiangtan Central Hospital
16
7
8
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
19%
3 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion
Role: collaborator
A Prospective Multicenter Observational Real-world Study of Retained Products of Conception
Role: collaborator
Endovascular Treatment for eXtra-Large Ischemic Stroke
Role: collaborator
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
Role: collaborator
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Role: collaborator
Clinical Study of Active Intervention in High-risk HFpEF Patients
Role: lead
Risk Factors In Heart Failure Patients With Preserved Ejection Fraction
Role: lead
Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
Role: lead
B-lines-guided Heart Failure Management in Heart Failure Patients
Role: lead
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Role: collaborator
Role of Hypothermia in Endovascular Stroke Thrombectomy
Role: collaborator
SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial
Role: collaborator
Multicenter Cohort Study of AAV in Hunan of China
Role: collaborator
Outcome of Discharged HFmrEF Patients
Role: lead
Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones
Role: collaborator
Cerebral Lesion and Neurocognitive Status Changes After TAVR
Role: collaborator
All 16 trials loaded